Gilead, EVOQ Unite on 'Potential Breakthrough' Treatment for RA, Lupus

Gilead Sciences and EVOQ Therapeutics kicked off 2023 with a new partnership to develop immunotherapies for rheumatoid arthritis (RA) and lupus, the companies announced Tuesday.

Gilead plans to utilize EVOQ’s proprietary NanoDisc technology, which the partners stated has “the potential to change the paradigm” for autoimmune disease treatment. It works by utilizing lymph-targeted delivery of disease-specific-antigens.